Grants & Programs


GITR, Inc., is a biotech company with interest in novel immunomodulatory responses to cancer. GITR owns a promising monoclonal antibody called TRX518 (anti-GITR, or glucocorticoid-induced tumor necrosis factor receptor) that is designed to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

TRX518 was the first anti-GITR candidate to enter human clinical trials, and is currently being studied in a phase I safety trial that was supported by an investment from CRI, and was designed and is managed in collaboration with CRI, Ludwig Cancer Research, and the CVC Trials Network.

Read a December 1, 2010, news release from Tolerx, the company that first owned TRX518 and later sold it to GITR, Inc., announcing our partnership here.